Related Experiment Videos
Anti-angiogenic therapy: rationale, challenges and clinical studies
R Longo1, R Sarmiento, M Fanelli
1Division of Medical Oncology, Azienda Complesso Ospedaliero, 'San Filippo Neri', Rome, Italy.
Angiogenesis
|August 9, 2003
Summary
Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and progression. Inhibiting this process offers a promising anticancer strategy, though clinical efficacy requires further optimization.
Area of Science:
- Oncology
- Vascular Biology
- Molecular Biology
Background:
- Angiogenesis is essential for normal physiological processes like wound healing and reproduction.
- Aberrant angiogenesis is implicated in diseases such as diabetes, psoriasis, rheumatoid arthritis, and cancer.
- Tumor development and progression are critically dependent on the switch to and maintenance of angiogenesis.
Purpose of the Study:
- To explore the molecular mechanisms regulating angiogenesis.
- To identify novel molecular targets for anti-cancer therapies.
- To evaluate the potential of anti-angiogenic strategies in cancer treatment.
Main Methods:
- Review of molecular alterations driving angiogenesis.
- Analysis of the role of endothelial cells (ECs) in vessel formation.
- Examination of pro- and anti-angiogenic factors and their regulation.
- Assessment of preclinical and clinical data on anti-angiogenic drugs.
Main Results:
- Angiogenesis involves complex, regulated steps including EC migration, lumen formation, and network assembly.
- Molecular alterations sustaining angiogenesis are key targets for anti-cancer drug development.
- Anti-angiogenic compounds show potent anticancer properties in preclinical studies.
- First-generation anti-angiogenic drugs demonstrated moderate clinical activity in advanced cancers.
Conclusions:
- Inhibiting angiogenesis presents advantages over conventional therapies due to EC accessibility and lower resistance rates.
- Targeting angiogenesis is a rational strategy for anti-cancer treatment.
- Optimizing therapeutic schedules and study designs is crucial for enhancing the clinical efficacy of anti-angiogenic drugs.